CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Chris Twelves

OPENALEX: A5021317857↗ORCID: 0000-0002-1849-7153↗

Affiliations

Organizations

Leeds Teaching Hospitals NHS Trustauthorship · GB University of Leedsauthorship · GB

Public evidence

1 connected articles

A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.2021 · Europe PMC

Registered research

Connected studies

A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastomanct01812616 A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastomanct01812603

Matched by exact identifiers only. Profile data: ORCID. Last retrieved 09/09/2026.

Chris Twelves - Medical Cannabis Research Engine